drugset / Trial / NCT07556484

Pharmacokinetics Of Emulsified Avacopan Applied By NG Tube

NCT07556484

Phase 1 Recruiting 6 enrolled Mayo Clinic
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the 72-hour pharmacokinetics of emulsified avacopan at a dose of 30 mg twice daily given to up to 6 patients with active severe GPA or MPA with diffuse alveolar hemorrhage (DAH) requiring mechanical ventilation for respiratory support.

Timeline

Start
2026-05
Primary completion
2028-03
Completion
2028-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Avacopan Small molecule 30 mg Other